These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37304271)

  • 1. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
    Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
    Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study.
    Küçükşahin O; Erden A; Karakaş Ö; Güven SC; Armağan B; Şahiner EŞ; İnan O; Kurtipek AC; Gemcioğlu E; Karaahmetoğlu S; Turan S; İzdeş S; Erdem D; Aypak A; Ayhan M; Akıncı E; Bodur H; Güner R; Omma A; Ateş İ
    Turk J Med Sci; 2022 Oct; 52(5):1486-1494. PubMed ID: 36422492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
    de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
    Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
    CORIMUNO-19 Collaborative group
    Lancet Respir Med; 2021 Mar; 9(3):295-304. PubMed ID: 33493450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
    Sundén-Cullberg J; Chen P; Häbel H; Skorup P; Janols H; Rasmuson J; Niward K; Östholm Balkhed Å; Chatzidionysiou K; Asgeirsson H; Blennow O; Parke Å; Svensson AK; Muvva JR; Ljunggren HG; ; Horne AC; Ådén U; Henter JI; Sönnerborg A; Vesterbacka J; Nowak P; Lampa J
    PLoS One; 2023; 18(12):e0295838. PubMed ID: 38157348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
    Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
    J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.
    Singh AK; Oks M; Husk G; Dechario SP; Mina B; Singh K; Kirschenbaum L; Carpati CM; Mahmoud O; Gabra NI; Ishikawa O; Altschultz E; Shah V; Mahajan A; Gautam A; Birnbaum B; Antonacci AC; Raoof S
    Respir Care; 2021 Dec; 66(12):1805-1814. PubMed ID: 34548407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis.
    Roumier M; Paule R; Vallée A; Rohmer J; Ballester M; Brun AL; Cerf C; Chabi ML; Chinet T; Colombier MA; Farfour E; Fourn E; Géri G; Khau D; Marroun I; Ponsoye M; Roux A; Salvator H; Schoindre Y; Si Larbi AG; Tchérakian C; Vasse M; Verrat A; Zuber B; Couderc LJ; Kahn JE; Groh M; Ackermann F;
    J Clin Immunol; 2021 Feb; 41(2):303-314. PubMed ID: 33188624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
    Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
    Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.
    Pontali E; Volpi S; Signori A; Antonucci G; Castellaneta M; Buzzi D; Montale A; Bustaffa M; Angelelli A; Caorsi R; Giambruno E; Bobbio N; Feasi M; Gueli I; Tricerri F; Calautti F; Castagnola E; Moscatelli A; Rollandi GA; Ravelli A; Cassola G; Sormani MP; Gattorno M
    J Allergy Clin Immunol; 2021 Apr; 147(4):1217-1225. PubMed ID: 33556464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center.
    Bektaş M; Yüce S; Ay M; Uyar MH; Önder ME; Kılıç Mİ
    Inflammopharmacology; 2023 Apr; 31(2):787-797. PubMed ID: 36707494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.
    Navarro-Millán I; Sattui SE; Lakhanpal A; Zisa D; Siegel CH; Crow MK
    Arthritis Rheumatol; 2020 Dec; 72(12):1990-1997. PubMed ID: 32602262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
    Aomar-Millán IF; Salvatierra J; Torres-Parejo Ú; Faro-Miguez N; Callejas-Rubio JL; Ceballos-Torres Á; Cruces-Moreno MT; Gómez-Jiménez FJ; Hernández-Quero J; Anguita-Santos F
    Intern Emerg Med; 2021 Jun; 16(4):843-852. PubMed ID: 33400157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous high-dose anakinra drops venous thrombosis and acute coronary syndrome in severe and critical COVID-19 patients: a propensity score matched study.
    Çakmak R; Yüce S; Ay M; Uyar MH; Kılıç Mİ; Bektaş M
    Sci Rep; 2024 May; 14(1):12369. PubMed ID: 38811592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.
    Başaran S; Şimşek-Yavuz S; Meşe S; Çağatay A; Medetalibeyoğlu A; Öncül O; Özsüt H; Ağaçfidan A; Gül A; Eraksoy H
    Int J Infect Dis; 2021 Apr; 105():756-762. PubMed ID: 33737128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study.
    Coloretti I; Busani S; Biagioni E; Venturelli S; Munari E; Sita M; DallAra L; Tosi M; Clini E; Tonelli R; Fantini R; Mussini C; Meschiari M; Guaraldi G; Cossarizza A; Alfano G; Girardis M
    Multidiscip Respir Med; 2021 Jan; 16(1):737. PubMed ID: 34040779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open label trial of anakinra to prevent respiratory failure in COVID-19.
    Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
    Elife; 2021 Mar; 10():. PubMed ID: 33682678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.